Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== Other inorganic compounds === Oxyhalides and oxysulfides of protactinium are known. PaOBr3 has a monoclinic structure composed of double-chain units where protactinium has coordination 7 and is arranged into pentagonal bipyramids. The chains are interconnected through oxygen and bromine atoms, and each oxygen atom is related to three protactinium atoms. PaOS is a light-yellow, non-volatile solid with a cubic crystal lattice isostructural to that of other actinide oxysulfides. It is obtained by reacting protactinium(V) chloride with a mixture of hydrogen sulfide and carbon disulfide at 900 °C. In hydrides and nitrides, protactinium has a low oxidation state of about +3. The hydride is obtained by direct action of hydrogen on the metal at 250 °C, and the nitride is a product of ammonia and protactinium tetrachloride or pentachloride. This bright yellow solid is thermally stable to 800 °C in vacuum. Protactinium carbide (PaC) is formed by the reduction of protactinium tetrafluoride with barium in a carbon crucible at a temperature of about 1400 °C. Protactinium forms borohydrides, which include Pa(BH4)4. It has an unusual polymeric structure with helical chains, where the protactinium atom has coordination number of 14 and is surrounded by six BH4− ions.
By the late 1930s, Thomas was embraced as the "poetic herald" for a group of English poets, the New Apocalyptics. Thomas refused to align himself with them and declined to sign their manifesto. He later stated that he believed they were "intellectual muckpots leaning on a theory". Despite this, many of the group, including Henry Treece, modelled their work on Thomas's. In the politically charged atmosphere of the 1930s Thomas's sympathies were very much with the radical left, to the point of his holding close links with the communists; he was also decidedly pacifist and anti-fascist. He was a supporter of the left-wing No More War Movement and boasted about participating in demonstrations against the British Union of Fascists. Bert Trick has provided an extensive account of an Oswald Mosley rally in the Plaza cinema in Swansea in July 1933 that he and Thomas attended.
After wiping out a small German force about 50 km (31 mi) east of the Italian capital on 3 June, the 6th Division advanced north and captured the town of Paliano, then doubled back to the south-west and moved on Rome, which was reached on the morning of 6 June. A Squadron, Pretoria Regiment—that unit's squadron of Rhodesian tanks—entered the city as part of the division's vanguard. The German commander Albert Kesselring fought a stubborn delaying action, gradually withdrawing his armies north with three Allied columns in pursuit, the 6th Armoured Division leading the most westerly spearhead of the Eighth Army in the centre. The mountainous terrain and the effective use of anti-tank weapons by the retreating Germans made the Allies' superiority in armour less decisive and slowed the Allied advance north to the banks of the Arno between June and August 1944, during which time the Rhodesian tank squadrons took part in Allied victories at Castellana, Bagnoregio and Chiusi.
Sources: en.wikipedia.org
== Further reading == Mullbacher A, Waring P, Eichner RD (1985). "Identification of an Agent in Cultures of Aspergillus fumigatus Displaying Anti-phagocytic and Immunomodulating Activity in vitro". Microbiology. 131 (5): 1251–1258. doi:10.1099/00221287-131-5-1251. PMID 2410548. Shah DT, Larsen B (1991). "Clinical isolates of yeast produce a gliotoxin-like substance". Mycopathologia. 116 (3): 203–208. doi:10.1007/BF00436836. PMID 1724551. S2CID 12919491. Jones RW, Hancock JG (1988). "Mechanism of Gliotoxin Action and Factors Mediating Gliotoxin Sensitivity". Microbiology. 134 (7): 2067–2075. doi:10.1099/00221287-134-7-2067. Schweizer M, Richter C (1994). "Gliotoxin Stimulates Ca2+ Release from Intact Rat Liver Mitochondria". Biochemistry. 33 (45): 13401–13405. doi:10.1021/bi00249a028. PMID 7524661. Scharf DH, Brakhage AA, Mukherjee PK (2016). "Gliotoxin - bane or boon?". Environmental Microbiology. 18 (4): 1096–1109. Bibcode:2016EnvMi..18.1096S. doi:10.1111/1462-2920.13080. PMID 26443473. Puri A, Ahmad A, Panda BP (2009). "Development of an HPTLC-based diagnostic method for invasive aspergillosis". Biomedical Chromatography. 24 (8): 887–92. doi:10.1002/bmc.1382. PMID 20033890.
=== Class I: Cys-based PTPs === Class I PTPs constitute the largest family. They contain the well-known classical receptor (a) and non-receptor PTPs (b), which are strictly tyrosine-specific, and the DSPs (c) which target Ser/Thr as well as Tyr and are the most diverse in terms of substrate specificity.
== History == The Council of Common Interests was formed under the 1973 Constitution of Pakistan. Until 2010 the body worked under Cabinet Division. After the passing of the 18th amendment the body was transferred to the Ministry of Inter Provincial Coordination on 4 March 2010.
== Chemistry == KNX-100 is a synthetic small molecule and peptide fragment of the oxytocin system. Its chemical structure has been disclosed by its developers in a patent. The chemical synthesis of KNX-100 has been described. The small-molecule oxytocin receptor agonists LIT-001 and LIT-002 are derivatives of KNX-100. The more-compact small-molecule oxytocin receptor agonists WJ0679 and CA7 are also analogues of KNX-100.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.